Provided by Tiger Trade Technology Pte. Ltd.

Warrior Met Coal LLC

106.60
-0.1300-0.12%
Post-market: 106.600.00000.00%17:15 EDT
Volume:728.75K
Turnover:78.30M
Market Cap:5.60B
PE:25.62
High:111.20
Open:107.23
Low:105.19
Close:106.73
52wk High:111.20
52wk Low:54.66
Shares:52.57M
Float Shares:51.78M
Volume Ratio:1.26
T/O Rate:1.41%
Dividend:0.32
Dividend Rate:0.30%
EPS(TTM):4.16
EPS(LYR):1.08
ROE:10.04%
ROA:5.17%
PB:2.45
PE(LYR):98.70

Loading ...

Press Release: Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient

Dow Jones
·
Mar 26

Press Release: Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Mar 23

HCC Wins Rs 1,662 Crore JV Contract for Mumbai Goregaon-Mulund Link Road Phase IV

TIPRANKS
·
Mar 19

Warrior Met Coal Is Maintained at Buy by Citigroup

Dow Jones
·
Mar 18

Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

GlobeNewswire
·
Mar 18

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance

GlobeNewswire
·
Mar 17

UBS Adjusts Price Target on Warrior Met Coal to $101 From $100, Maintains Buy Rating

MT Newswires Live
·
Mar 12

Warrior Met Coal Inc : UBS Raises Target Price to $101 From $100

THOMSON REUTERS
·
Mar 12

Warrior Met Coal Inc. announced its annual stockholders meeting

Reuters
·
Mar 10

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

GlobeNewswire
·
Mar 04

Can-Fite’s Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

GlobeNewswire
·
Mar 04

Warrior Met Coal Inc : B. Riley Raises Target Price to $120 From $74

THOMSON REUTERS
·
Mar 03

B. Riley Adjusts Price Target on Warrior Met Coal to $120 From $74, Maintains Buy Rating

MT Newswires Live
·
Mar 03

Warrior Met Coal (HCC) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Feb 27